Your browser doesn't support javascript.
loading
Opportunistic Infections, Mortality Risk, and Prevention Strategies in Patients With Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome.
Czech, Mary; Cuellar-Rodriguez, Jennifer; Patel, Bhavisha A; Groarke, Emma M; Cowen, Edward W; Turturice, Benjamin; Beck, David B; Wilson, Lorena; Goodspeed, Wendy; Darden, Ivana; Young, Neal S; Hickstein, Dennis; Ombrello, Amanda; Hoffman, Patrycjia; Arikan, Evsen Apaydin; Sinaii, Ninet; Hathaway, Londa; Castelo-Soccio, Leslie; Fike, Alice; Kastner, Daniel B; Grayson, Peter C; Ferrada, Marcela A.
Afiliação
  • Czech M; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Cuellar-Rodriguez J; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Patel BA; National Heart, Blood, and Lung Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Groarke EM; National Heart, Blood, and Lung Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Cowen EW; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Turturice B; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Beck DB; Department of Medicine and Department of Biochemistry and Molecular Pharmacology, New York University, New York, New York, USA.
  • Wilson L; National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Goodspeed W; National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Darden I; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Young NS; National Heart, Blood, and Lung Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Hickstein D; National Heart, Blood, and Lung Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Ombrello A; National Heart, Blood, and Lung Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Hoffman P; National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Arikan EA; National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Sinaii N; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Hathaway L; Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Castelo-Soccio L; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Fike A; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Kastner DB; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Grayson PC; National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Ferrada MA; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Open Forum Infect Dis ; 11(7): ofae405, 2024 Jul.
Article em En | MEDLINE | ID: mdl-39077052
ABSTRACT

Background:

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a genetic disorder characterized by bone marrow failure and systemic inflammation, putting patients at risk for infections. This study comprehensively examines the prevalence of opportunistic infections in patients with VEXAS, evaluating their impact on clinical outcomes and potential preventive measures.

Methods:

Patients with confirmed VEXAS were included. Survival analysis and logistic regression were used to identify associations between opportunistic infections and mortality. Infection rates (IRs) for Pneumocystis jirovecii pneumonia (PJP) and alphaherpesviruses were calculated over a prospective 8-month observation period in relationship to prophylaxis.

Results:

Of 94 patients with VEXAS, 6% developed PJP; 15% had alphaherpesvirus reactivation, with varicella zoster virus (VZV) being the most common herpesvirus; and 10% contracted a nontuberculous mycobacterial (NTM) infection. Risk of death was significantly increased per month following a diagnosis of PJP (hazard ratio [HR], 72.41 [95% confidence interval {CI}, 13.67-533.70]) or NTM (HR, 29.09 [95% CI, 9.51-88.79]). Increased odds for death were also observed in patients with a history of herpes simplex virus (HSV) reactivation (odds ratio [OR], 12.10 [95% CI, 1.29-114.80]) but not in patients with VZV (OR, 0.89 [95% CI, .30-2.59]). Prophylaxis for PJP (IR, 0.001 vs 0 per person-day, P < .01) and VZV (IR, 0.006 vs 0 per person-day, P = .04) markedly decreased infection rates with a number needed to treat of 4 and 7, respectively.

Conclusions:

Opportunistic infections are common in patients with VEXAS. Patients who develop PJP, HSV, or NTM are at increased risk for death. Prophylaxis against PJP and VZV is highly effective.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article